Skip to the answer

Arformoterol Oral Inhalation

Arformoterol is a long-acting bronchodilator used as a twice-daily maintenance treatment for chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brand name Brovana
Drug class Beta2-adrenergic Agonist
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 15 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 7, 2026
Arformoterol Oral Inhalation at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Arformoterol (Brovana) is a twice-daily nebulized bronchodilator that relaxes airway muscles to keep COPD airways open, often picked for people who struggle with handheld inhalers; it dates to about 2006 and is available generically. Most people tolerate it well, with mostly mild effects such as a faster heartbeat, shakiness, leg cramps or back pain. It carries a boxed warning that drugs in its class raise the risk of asthma-related hospitalization and death when used alone for asthma, so it is for COPD only. It is not a rescue medicine, so keep a quick-relief inhaler handy, never add extra doses, and call your prescriber if you need that inhaler more often.

Clinical pearls

  • Store the vials in the fridge inside their foil pouch, put unused ones back, and use an opened vial right away.
  • Do not mix it with other nebulizer medicines in the same cup; give each one separately.
  • Tell any prescriber starting a beta-blocker that you use this, because beta-blockers can blunt it and tighten your airways.
  • If you take a water pill or a steroid, ask whether your potassium should be checked, since these together can lower it.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInhalation solution (nebulizer)
Earliest FDA record2006
Companies listing it with the FDA15
FDA label last updatedAug 20, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Arformoterol Oral Inhalation, written from its FDA label.

What Arformoterol Oral Inhalation is used for

▾

Arformoterol oral inhalation solution is approved for the following use:

  • Long-term maintenance treatment of COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema — taken twice daily to reduce ongoing airway narrowing (bronchoconstriction)
  • It is not indicated for the treatment of sudden (acute) COPD worsening or flare-ups
  • It is not indicated for asthma — its safety and effectiveness in asthma have not been established

How Arformoterol Oral Inhalation works

▾

Arformoterol is the active form of formoterol — specifically the (R,R)-enantiomer (the molecular shape that does most of the work). It selectively activates beta-2 receptors in the smooth muscle that wraps around the airways. Activating those receptors triggers a cascade inside the cell that raises levels of a molecule called cyclic AMP, which causes the airway muscles to relax and the airways to widen. Arformoterol also reduces the release of inflammatory chemicals like histamine and leukotrienes from mast cells in the lungs, which helps limit airway irritation.

Because beta-2 receptors also exist in the heart (making up 10–50% of the heart's beta receptors), even this targeted drug can have some cardiac effects — which is why heart monitoring is part of its safety profile.

Arformoterol Oral Inhalation dosage

▾

Arformoterol tartrate inhalation solution is taken twice daily — once in the morning and once in the evening — using a standard jet nebulizer connected to an air compressor. Each dose is a single ready-to-use liquid vial; the entire contents of one vial are placed in the nebulizer for each treatment. It should not be mixed with other nebulizer medications. Store vials in the refrigerator inside their foil pouches; once a pouch is opened, return unused vials to the pouch and use any opened vial right away.

  • Take it at roughly the same times each day (morning and evening)
  • Do not take extra doses if symptoms worsen — contact your doctor instead
  • Always follow your prescriber's specific instructions

Dosing details from the FDA-approved label

From the Arformoterol Oral Inhalation prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Maintenance treatment of COPD (adults)
    • One 15 mcg unit-dose vial administered twice daily (morning and evening) by nebulization
    • One 15 mcg/2 mL vial every 12 hours
    • Maximum: A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended
  • Patients with renal or hepatic impairment
    • No dose adjustment is required
    • clearance prolonged in hepatic impairment; monitor closely
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION The recommended dose of arformoterol tartrate inhalation solution is one 15 mcg unit-dose vial administered twice daily (morning and evening) by nebulization. A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended. Arformoterol tartrate inhalation solution should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor (see the accompanying Patient Information ). Arformoterol tartrate inhalation solution should not be swallowed. Arformoterol tartrate inhalation solution should be stored refrigerated in foil pouches. After opening the pouch, unused unit-dose vials should be returned to, and stored in, the pouch. An opened unit-dose vial should be used right away. If the recommended maintenance treatment regimen fails to provide the usual response, medical advice should be sought immediately, as this is often a sign of destabilization of COPD. Under these circumstances, the therapeutic regimen should be reevaluated and additional therapeutic options should be considered. No dose adjustment is required for patients with renal or hepatic impairment. However, since the clearance of arformoterol tartrate inhalation solution is prolonged in patients with hepatic impairment, they should be monitored closely. The drug compatibility (physical and chemical), efficacy, and safety of arformoterol tartrate inhalation solution when mixed with other drugs in a nebulizer have not been established. The safety and efficacy of arformoterol tartrate inhalation solution have been established in clinical trials when administered using the PARI LC ® Plus nebulizer (with a face mask or mouthpiece) and the PARI DURA NEB ™ 3000 compressor. The safety and efficacy of arformoterol tartrate inhalation solution delivered from non-compressor based nebulizer systems have not been established. For oral inhalation only. • A total daily dose of greater than 30 mcg is not recommended. ( 2 ) • One 15 mcg/2 mL vial every 12 hours. ( 2 ) • For use with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. ( 2 )

Read the full Dosage and Administration section on DailyMed →

Arformoterol Oral Inhalation side effects

▾

The most commonly reported side effects (occurring in at least 2% of patients in clinical trials) include:

Common side effects

  • Pain (general body pain)
  • Chest pain
  • Back pain
  • Diarrhea
  • Sinusitis (sinus inflammation)
  • Leg cramps
  • Skin rash
  • Flu-like symptoms
  • Swelling in the legs or feet (peripheral edema)

When to get medical help

  • Call your doctor right away if your breathing gets worse or your rescue inhaler stops working as well as usual — this can signal that your COPD is getting worse
  • Seek emergency help if you experience sudden, severe wheezing right after using the nebulizer (paradoxical bronchospasm — airway tightening caused by the medication itself)
  • Tell your doctor if you notice a fast or irregular heartbeat, chest pain, or significant increase in blood pressure
  • Get medical help immediately for signs of a serious allergic reaction: hives, swelling of the face or throat, or rash after using the medication
  • Contact your doctor if you feel significant muscle weakness, unusual shakiness, or symptoms of low potassium (such as muscle cramps or irregular heartbeat)
  • Do not use extra doses to compensate for worsening symptoms — seek medical attention instead

Arformoterol Oral Inhalation warnings and precautions

▾
  • Not a rescue inhaler: Arformoterol will not relieve a sudden COPD attack. Always have a short-acting beta-agonist inhaler available for acute symptoms.
  • Do not exceed the recommended dose: Using more than prescribed — or using it alongside other long-acting bronchodilators — can cause serious, potentially fatal cardiovascular effects.
  • Paradoxical bronchospasm: In rare cases, the medication can cause the airways to tighten immediately after use. Stop using it and get emergency help if this happens.
  • Heart effects: Arformoterol can increase heart rate and blood pressure, and may cause changes in heart rhythm, especially at higher doses. Use with caution if you have a heart condition.
  • Low potassium and high blood sugar: This medication can temporarily lower potassium levels and raise blood sugar — a concern if you have diabetes or take diuretics.
  • Liver disease: The drug clears more slowly in people with liver impairment, so closer monitoring is needed.
  • Worsening COPD: Needing your rescue inhaler more often, or finding it less effective, is a warning sign. Seek medical attention promptly — do not simply increase your arformoterol dose.

Arformoterol Oral Inhalation interactions

▾

Arformoterol can interact with several types of medications — tell your doctor and pharmacist about everything you take:

  • Other adrenergic (stimulant) drugs: Can amplify arformoterol's cardiovascular effects like fast heart rate
  • MAO inhibitors and tricyclic antidepressants: Significantly intensify heart-related side effects — use with extreme caution
  • QTc-prolonging drugs (certain antibiotics, antipsychotics, antiarrhythmics): Increase risk of dangerous heart rhythm problems
  • Beta-blockers: Block arformoterol's bronchodilating effect and may trigger severe airway tightening in COPD patients
  • Theophylline / aminophylline (xanthine-type drugs): Can further raise heart rate and blood pressure when used together
  • Non-potassium-sparing diuretics (loop or thiazide water pills): Can worsen low potassium levels and heart rhythm changes
  • Corticosteroids and other diuretics: May increase the risk of low potassium (hypokalemia)

Interactions listed in the FDA-approved label

From the Arformoterol Oral Inhalation prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Other adrenergic drugs: The sympathetic effects of arformoterol may be potentiated. Use with caution.
  • Xanthine derivatives (methylxanthines such as aminophylline, theophylline): May potentiate any hypokalemic effect of adrenergic agonists including arformoterol; concurrent use of intravenous or oral methylxanthines has not been completely evaluated. Use with caution.
  • Steroids: May potentiate any hypokalemic effect of adrenergic agonists including arformoterol. Use with caution.
  • Diuretics, including non-potassium sparing diuretics (loop or thiazide): ECG changes and/or hypokalemia may be acutely worsened by beta-agonists, especially when the recommended beta-agonist dose is exceeded. Caution is advised in co-administration.
  • MAO inhibitors: The effect of adrenergic agonists on the cardiovascular system may be potentiated. Administer with extreme caution.
  • Tricyclic antidepressants: The effect of adrenergic agonists on the cardiovascular system may be potentiated. Administer with extreme caution.
  • Drugs known to prolong the QTc interval: Cardiovascular effect of adrenergic agonists may be potentiated; these drugs have an increased risk of ventricular arrhythmias. Administer with extreme caution.
  • Beta-blockers: They may inhibit each other's effect; beta-blockers block the therapeutic effects of beta-agonists and may produce severe bronchospasm in COPD patients. Patients with COPD should not normally be treated with beta-blockers; where no alternative exists, cardioselective beta-blockers could be considered, with caution.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Other adrenergic drugs may potentiate effect. Use with caution. ( 5.3 , 7.1 ) • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. Use with caution. ( 5.7 , 7.2 , 7.3 ) • MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. Use with extreme caution.( 7.4 ) • Beta-blockers may decrease effectiveness. May block bronchodilatory effects of beta-agonists. Use with caution and only when medically necessary.( 7.5 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of arformoterol may be potentiated [ see Warnings and Precautions ( 5.3 , 5.5 , 5.6 , 5.7 ) ]. 7.2 Xanthine Derivatives, Steroids, or Diuretics Concomitant treatment with methylxanthine (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists including arformoterol tartrate inhalation solution [ see Warnings and Precautions (5.7) ]. The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving arformoterol tartrate inhalation solution has not been completely evaluated. In two combined 12-week, placebo-controlled trials that included arformoterol tartrate inhalation solution doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 arformoterol tartrate inhalation solution -treated subjects received concomitant theophylline at study entry. In a 12-month controlled trial that included a 50 mcg once daily arformoterol tartrate inhalation solution dose, 30 of the 528 arformoterol tartrate inhalation solution-treated subjects received concomitant theophylline at study entry.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿32 supplements and herbs with documented Arformoterol Oral Inhalation interactions, ranked by severity Check Arformoterol Oral Inhalation against a supplement or herb →

Before taking Arformoterol Oral Inhalation

▾
  • Do not use arformoterol if you have ever had an allergic reaction to arformoterol, formoterol, or any component of this product
  • Tell your doctor if you have any heart condition — including coronary artery disease, arrhythmias (irregular heartbeat), or high blood pressure
  • Tell your doctor if you have a seizure disorder, an overactive thyroid (thyrotoxicosis), or diabetes
  • Tell your doctor if you have liver disease — arformoterol exposure is increased and you will need closer monitoring; no dose adjustment is required but monitoring is important
  • Pregnancy: animal studies at very high doses showed fetal harm; this medication should only be used during pregnancy if the benefit clearly outweighs the potential risk — discuss with your doctor
  • Breastfeeding: it is unknown whether arformoterol passes into human breast milk; weigh the benefits of breastfeeding against any potential risk and discuss with your doctor
  • Children: this medication is not approved for pediatric use; COPD does not occur in children
  • Older adults (65+): no major differences in safety or effectiveness were found compared to younger patients, but some older individuals may be more sensitive — stick strictly to the recommended dose

Arformoterol Oral Inhalation overdose

▾

Taking too much arformoterol can cause excessive beta-receptor stimulation, leading to a very fast heart rate (up to 200 beats per minute), irregular heartbeat, chest pain, high or low blood pressure, tremor, headache, nervousness, nausea, dizziness, low potassium, and elevated blood sugar. In serious cases, cardiac arrest and death are possible. If overdose is suspected, stop using the medication and get emergency medical help immediately — cardiac monitoring is recommended.

What Arformoterol Oral Inhalation does in the body

▾

Arformoterol relaxes the smooth muscle around the airways by activating beta-2 receptors, which leads to widening of the airways and easier breathing. It can also cause system-wide beta-receptor effects, including modest, temporary decreases in blood potassium and increases in blood sugar. At the recommended dose, its effect on the heart's electrical rhythm (QTc interval) is minimal, though higher doses have been associated with more cardiac rhythm changes in clinical monitoring studies. Heart rate increases of roughly 9–12 beats per minute above baseline have been observed across dosing studies.

How your body processes Arformoterol Oral Inhalation

▾

After nebulization, arformoterol is absorbed primarily through the lungs into the bloodstream, reaching peak plasma levels in about 30 minutes. It is broken down mainly in the liver — first by a process called glucuronidation (attaching a sugar molecule to the drug) and secondarily by enzymes CYP2D6 and CYP2C19. The drug has a long half-life of about 26 hours in COPD patients, which supports its twice-daily dosing. Most of the drug and its metabolites are excreted in the urine (about 67%) with smaller amounts in the stool. People with liver impairment have higher drug exposure and should be monitored more closely, though no dose adjustment is required.

How to store Arformoterol Oral Inhalation

▾

Store Arformoterol Tartrate Inhalation Solution in the protective foil pouch under refrigeration at 36° to 46°F (2° to 8°C). Protect from light and excessive heat. stored in, the pouch.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

32

Supplements & herbs that interact with Arformoterol Oral Inhalation

32 supplements and herbal products have documented interactions with Arformoterol Oral Inhalation in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 1
  • Moderate · 22
  • Minor · 9
ACTIVATED CHARCOAL Major BLACK TEA Moderate CAFFEINE Moderate COCOA Moderate COFFEE Moderate COFFEE CHARCOAL Moderate COLA NUT Moderate EPHEDRA Moderate +24 more
Every supplement checked against Arformoterol Oral Inhalation — ranked by severity The full interaction hub: 1 major · 22 moderate · 9 minor · every one linked to its full report. Check Arformoterol Oral Inhalation against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Arformoterol Oral Inhalation: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Arformoterol Oral Inhalation — the kind of thing our pharmacy team would talk through with you at the counter.

Can I use arformoterol when I'm having a sudden breathing attack?

▾
No — arformoterol is not a rescue medication. It works gradually over time to keep your airways open, but it won't act fast enough to help during an acute flare-up. Your doctor should also prescribe a short-acting rescue inhaler (like albuterol) for those moments. Always keep that rescue inhaler with you, and if you're needing it more and more often, let your doctor know right away — that's a sign your COPD may be getting worse.

How do I use the nebulizer correctly?

▾
You'll use a standard jet nebulizer connected to an air compressor — your pharmacist or doctor's office can show you the setup. Each dose comes as a single ready-to-use liquid vial. Pour the whole vial into the nebulizer cup, then breathe in the mist through the mouthpiece or face mask until the vial is empty. Take one treatment in the morning and one in the evening, about 12 hours apart. Don't mix arformoterol with other liquid medications in the nebulizer unless your doctor specifically says to.

What side effects should I watch out for?

▾
The most common ones are body aches, back pain, diarrhea, leg cramps, and flu-like symptoms — these are generally manageable. What you want to call your doctor about right away are things like a noticeably fast or pounding heartbeat, new chest pain, or if your breathing suddenly gets much worse right after using the nebulizer. That last one — called paradoxical bronchospasm — is rare but means you need to stop the medication and get help immediately.

I take a water pill (diuretic) and a heart medication. Is that a problem?

▾
It's worth flagging for your doctor. Certain diuretics — especially loop or thiazide water pills — can lower your potassium level, and arformoterol can do the same thing. Using both together can make that drop more significant, which can affect your heart rhythm. Some heart medications called beta-blockers can also interfere with how arformoterol works and may even tighten your airways. Make sure your prescribing doctor knows about every medication you take so they can keep an eye on things.

I have liver disease. Is it safe for me to use this?

▾
You can still use arformoterol if your doctor prescribes it, but your liver plays a key role in breaking down this medication. If your liver isn't working at full capacity, arformoterol can build up more in your body than usual. Your doctor doesn't need to change your dose, but they will want to monitor you more closely. Just make sure they know about your liver condition before you start.

I'm pregnant — can I keep using arformoterol?

▾
This is a conversation to have with your doctor as soon as possible. There are no solid studies in pregnant women, and animal studies at very high doses did show some concerns for the fetus. That said, untreated COPD can also carry risks during pregnancy. Your doctor will weigh the benefits against the potential risks and help you decide the safest path forward. If you become pregnant while using arformoterol, let your doctor know right away.

Is Arformoterol Oral Inhalation available over the counter?

▾
No. Arformoterol Oral Inhalation is a prescription medicine: every Arformoterol Oral Inhalation product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Arformoterol Oral Inhalation first available?

▾
The earliest FDA record we hold for Arformoterol Oral Inhalation is from 2006: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Arformoterol Oral Inhalation was first used.

Who makes Arformoterol Oral Inhalation?

▾
15 companies currently list Arformoterol Oral Inhalation products in the FDA's NDC Directory, including Alembic Pharmaceuticals Inc., American Health Packaging, Aucta Pharmaceuticals, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Arformoterol Oral Inhalation on HelloPharmacist

📊Arformoterol Oral Inhalation supplement interactions32 checked — ranked by severity 🌿Drug & Supplement CheckerArformoterol Oral Inhalation vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Arformoterol Oral Inhalation NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Arformoterol Oral Inhalation Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Arformoterol Oral Inhalation forms and strengths (how it comes)

Arformoterol Oral Inhalation is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Arformoterol Oral Inhalation inactive ingredients by manufacturer.

Inhalation solution (nebulizer)

Inhaled
Brands Brovana
How this form is used
What it may be used for
  • Arformoterol Tartrate inhalation solution is used for long-term, twice-daily maintenance treatment of airway narrowing (bronchoconstriction) in adults with COPD, including chronic bronchitis and emphysema
  • Brovana is used for the same long-term, twice-daily maintenance treatment of bronchoconstriction in adults with COPD, including chronic bronchitis and emphysema
  • Not for relief of sudden COPD attacks or for treatment of asthma
Important instructions
  • Arformoterol Tartrate and Brovana inhalation solutions are used with a standard jet nebulizer connected to an air compressor — never swallowed
  • Use one unit-dose vial in the nebulizer in the morning and one in the evening, approximately 12 hours apart
  • Store vials refrigerated in their foil pouches; return unused vials to the pouch after opening, and use any opened vial immediately
  • Do not mix with other medications in the nebulizer — compatibility with other drugs has not been established
Available strengths 1 strength
15 mcg/2 mL
26 FDA-listed product records ⓘ

Arformoterol Oral Inhalation on the U.S. market: products, makers and brands

How Arformoterol Oral Inhalation appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

15 companies list 15 Arformoterol Oral Inhalation product records with the FDA, mostly as inhalation solution (nebulizer); the earliest marketing or approval year on record is 2006. Brand names on the directory include Brovana; the rest are generics.

1
Dose forms ⓘ
15
Labelers (makers, repackagers, distributors)
3
Brand names
15
FDA-listed product records ⓘ
2006
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (5) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Alembic Pharmaceuticals Inc.7%
American Health Packaging7%
Aucta Pharmaceuticals, Inc.7%
Cipla USA Inc.7%
Devatis, Inc.7%
Dr. Reddy's Laboratories, Inc.7%
Other makers60%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Arformoterol Oral Inhalation is used (Medicaid data)

A general measure of how commonly Arformoterol Oral Inhalation is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Arformoterol Oral Inhalation is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

17,345
Medicaid prescriptions filled (Q1–Q4 2025)
$1.6M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Arformoterol Oral Inhalation prescribed? Of the 1,601 medications we measure, Arformoterol Oral Inhalation ranks #826 by Medicaid prescriptions — more than 48% of them.

Where Arformoterol Oral Inhalation ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #826 of 1,601
#821 Citric Acid / Lactic A... 17,596 Rx #822 Phenylephrine 17,563 Rx #823 Fenfluramine 17,553 Rx #824 Fam-trastuzumab deruxt... 17,489 Rx #825 Oxymetazoline Nasal Sp... 17,358 Rx #826 Arformoterol Oral Inha... 17,345 Rx #827 Colesevelam 17,250 Rx #828 Itraconazole 17,092 Rx #829 Potassium Acetate 16,989 Rx #830 Theophylline 16,886 Rx #831 Raltegravir 16,834 Rx

Utilization by Arformoterol Oral Inhalation product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

arformoterol 0.0075 MG/ML Inhalation Solution

17,345 Medicaid prescriptions (Q1–Q4 2025) 100% of Arformoterol Oral Inhalation prescriptions shown $1.6M gross reimbursement (before rebates) ≈ $95 per prescription (gross)

Summed across the 16 of 62 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 668956

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Arformoterol Oral Inhalation, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 16 of 62 listed Arformoterol Oral Inhalation NDCs with Medicaid activity.

Compare Arformoterol Oral Inhalation products

A representative set of FDA-listed product records for Arformoterol Oral Inhalation — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 15 of 15 products — FDA National Drug Code Directory. See every product, package size and price: browse all 15 Arformoterol Oral Inhalation NDCs →

Arformoterol Oral Inhalation recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list one Arformoterol recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.

Class II Sep 29, 2022 · Terminated · CIPLA
Lack of Assurance of Sterility: environmental monitoring failure.
  • Arformoterol Tartrate Inhalation Solution, 15 mcg/2mL, 2 mL Sterile Unit-Dose Vial packaged in 5 x 2 mL Sterile Unit-Dose Vials per pouch, NDC 69097-168-48; 60 (12 x 5) x 2 mL Sterile Unit-Dose Vials… Lots: Batch No: IA10082, IA10083, IA10084, IA10085, IA10086, exp. date 01/2023; IA10122, IA10123, IA10124, IA10125, IA10126, IA10127, IA10128, IA10129, IA10130, exp. date 02/2023 FDA record D-1550-2022 →

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Arformoterol Oral Inhalation RxCUI 304962 1 dose form · 1 strength
  1. Dose form (SCDF) Inhalation Solution RxCUI 2108276 In current FDA listings
    Clinical drug / strength (SCD) 0.0075 MG/ML RxCUI 668956

Look up RxCUI 304962 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Arformoterol Oral Inhalation costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Solution · Respiratory (inhalation) 15 mcg/2 mL $0.633 per mL NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Arformoterol Oral Inhalation brand names

Arformoterol Oral Inhalation is sold under one brand name in the FDA directory — Brovana. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Brovana

Who makes Arformoterol Oral Inhalation: manufacturers and labelers

15 companies list Arformoterol Oral Inhalation products with the FDA. By number of product records, the largest are Alembic Pharmaceuticals Inc., American Health Packaging, Aucta Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Alembic Pharmaceuticals Inc. 1 American Health Packaging 1 Aucta Pharmaceuticals, Inc. 1 Cipla USA Inc. 1 Devatis, Inc. 1 Dr. Reddy's Laboratories, Inc. 1 Fosun Pharma USA Inc. 1 Ingenus Pharmaceuticals, LLC 1 Lifestar Pharma LLC 1 Lupin Pharmaceuticals, Inc. 1 Micro Labs Limited 1 NorthStar RxLLC 1 Ritedose Pharmaceuticals, LLC 1 Slate Run Pharmaceuticals 1 Sun Pharmaceutical Industries, Inc. 1

Arformoterol Oral Inhalation drug class (RxNorm)

Arformoterol Oral Inhalation belongs to the beta2-Adrenergic Agonist class.

Pharmacologic class beta2-Adrenergic Agonist
How it works Adrenergic beta2-Agonists

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Arformoterol Oral Inhalation page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Aug 20, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Arformoterol Oral Inhalation.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Arformoterol Oral Inhalation after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
15
Finished products in the current FDA directory
15
Companies listing them (makers, repackagers, distributors)
15
FDA labeler codes behind them ⓘ
15
Linked representative label ⓘ
American Health Packaging
Linked label effective
Aug 20, 2026
Composite sections available
24
Linked SPL Set ID
bb1a6643-f280-4f02-a824-0428a2b82d3c
Linked SPL Document ID
59809098-ffd3-5958-e063-6294a90a827b
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. American Health Packaging is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →